- Company
- Heart failure guidelines revised for the first time in 6 yrs
- by Jul 25, 2022 05:57am
- The clinical practice guidelines for heart failure have been completely revised for the first time in 6 years. The new guideline contains all the latest drugs ranging from SGLT-2 inhibitors that demonstrated an effect in heart failure, angiotensin receptor-neprilysin inhibitors (ARNIs) that are represented by the Entresto, to the recently approv
- Company
- How will the prescription market react?
- by Chon, Seung-Hyun Jul 25, 2022 05:57am
- Pharmaceutical companies are also paying keen attention to the rapid increase in the number of COVID-19 confirmed cases this month. Since the spread of COVID-19 in the past two years, the prescription market seems to be closely watching recent changes in the situation. According to the Central Disease Control Headquarters of the Korea Centers
- Company
- Strong dollar slows sales of Epis’s 3 biosimilars in Europe
- by Jul 22, 2022 05:53am
- The 3 autoimmune disorder biosimilars developed by Samsung Bioepis (Benepali, Imraldi, Flixabi) made slower sales in Europe in the first half of this year. Total sales fell by 4.7% compared to the previous year. Sales of the products had suffered a hard blow from the recent strong dollar and the continued pressure to cut prices. According
- Company
- Takeda's anti-cancer drug Exkivity has been approved
- by Jul 22, 2022 05:53am
- A second targeted anticancer drug targeting EGFR Exxon 20 insertion mutation has emerged. Takeda Pharmaceutical Korea announced on the 20th that it has received approval from the Ministry of Food and Drug Safety for the EGFR Exxon 20 insertion mutant non-small cell lung cancer treatment Exkivity (Mobocertinib). Exkivity is a TKI that inhib
- Company
- Imbruvica makes 4th attempt to extend reimbursement
- by Eo, Yun-Ho Jul 21, 2022 06:04am
- Already for the fourth time, Janssen is attempting to expand reimbursement for ‘Imbruvica’ as a first-line treatment. According to industry sources, reimbursement of Imbruvica (ibrutinib) as a first-line treatment for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Leukemia (SLL) will once again be deliberated by the Health Ins
- Company
- Tabrecta is scheduled to be introduced in August
- by Eo, Yun-Ho Jul 20, 2022 05:50am
- MET anticancer drugs will enter the first stage of registration of insurance benefits. According to related industries, Tabrecta will be introduced to the HIRA Cancer Disease Review Committee on August 10. Tabrecta was approved in Korea in November last year as a non-small cell Lung Cancer (NSCLC) treatment that confirmed MET Exxon 14 deficie
- Company
- Moderna to soon release bivalent COVID-19 vaccine
- by Jul 20, 2022 05:49am
- Moderna is determined to promptly commercialize its new bivalent COVID-19 vaccine “mRNA-1273.214 (214)” in Korea. On the morning of the 19th, Moderna held a “Moderna’s mRNA technology and strategy in the endemic era” press conference at JW Mariott Hotel. At the conference, the company stated that it can “supply the 214 globally by the
- Company
- Big Pharma are making all efforts to preoccupy orphan drugs
- by Jul 20, 2022 05:49am
- New drugs are emerging one after another for rare diseases such as multiple Castleman's disease, beta thalassemia, Fabri's disease, and spinal muscular dystrophy, which were not well known and had no medicine. Global pharmaceutical companies such as Johnson & Johnson, AstraZeneca, and Roche are leading new drugs for rare diseases. It was suggest
- Company
- Maximizing JW Pharma's platform technology
- by Chon, Seung-Hyun Jul 20, 2022 05:48am
- JW Group is implementing an active open innovation strategy to maximize R&D capabilities. In order to boost the potential of two core platform technologies developed by themselves, they are mobilizing all resources that can be utilized from domestic bio ventures to overseas investment institutions. According to industries on the 13th, JW Grou
- Company
- Novartis nears reimb for its 2 ultra-high-priced new drugs
- by Eo, Yun-Ho Jul 19, 2022 05:16am
- With Novartis Korea nearing reimbursement listing for its 2 ultra high-priced drugs, how the two drugs will progress is receiving attention. The two Novartis drugs that have continuously raised issues since its domestic approval are ‘Kymriah (tisagenlecleucel) and Zolgensma (onasemnogene abeparvovec-xioi). Among the two drugs, Kymirah was fi
